IntelGenx (CVE:IGX) said today that Health Canada approved its application to study its montelukast VersaFilm therapy in adults with mild to moderate Alzheimer’s disease.
The Phase IIa proof-of-concept trial is slated to begin screening patients in the first quarter of next year.
Get the full story at our sister site, Drug Delivery Business News.